Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study - Concepedia

Concepedia

Publication | Open Access

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

DOI Full Paper Access

130

Citations

24

References

2008

Year

Regina I. Jakacki, Marta Hamilton, Richard J. Gilbertson, Susan M. Blaney, Jean M. Tersak, Mark Krailo, Ashish M. Ingle, Stephan D. Voss, Janet Dancey, Peter C. Adamson

Journal of Clinical Oncology

Abstract

The recommended phase II dose of erlotinib in recurrent pediatric solid tumors is 85 mg/m(2)/d, either alone or in combination with temozolomide.

References

	Year	Citations

Page 1